ANVS · Annovis Bio, Inc.
$1.75
-0.07 (-3.85%)
At close · Aug 24
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Management's plans to mitigate this risk include raising additional capital through equity financings, debt, or other potential alternatives. Management's plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, Management has concluded that such plans do not alleviate the aforementioned substantial doubt.”View the 10-Q filed Aug 14, 2026
Market Cap
$77.54M
Shares
42.61M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2025
Net Income
-$28.85M
-17.3%
FY2025
Diluted EPS
-$1.40
+39.4%
FY2025
Operating Cash Flow
-$25.62M
-17%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| $43.77M | $25.22M | $20M | $38.79M | $16.52M | $8.48M | $3.05M | $776.26K | |
| $5.76M | $4.48M | $6.7M | $6.24M | $9M | $6.06M | $3.59M | $829.37K | |
| $49.53M | $29.7M | $26.69M | $45.04M | $25.51M | $14.54M | $6.64M | $1.61M | |
| -$49.53M | -$29.7M | -$26.69M | -$45.04M | -$25.51M | -$14.54M | -$6.64M | -$1.61M | |
| $618.09K | $699.06K | $331.85K | $667.9K | — | — | — | — | |
| $6751 | $841.06K | $2.1M | -$11.17M | $182.71K | $50.09K | $1.18M | $614.64K | |
| -$40.94M | — | — | -$56.2M | -$25.33M | -$14.49M | -$5.46M | -$990.98K | |
| $0 | $0 | — | — | — | — | — | $0 | |
| -$49.52M | -$28.85M | -$24.59M | -$56.2M | -$25.33M | -$14.49M | -$5.46M | -$990.98K | |
| USD/shares | — | -$1.40 | -$2.02 | -$6.23 | -$3.10 | -$1.90 | -$0.87 | — |
| USD/shares | — | -$1.40 | -$2.31 | -$6.23 | -$3.10 | -$1.90 | -$0.87 | — |
| shares | — | 20.55M | 12.18M | 9.02M | 8.16M | 7.63M | 6.31M | 282.61K |
| shares | — | 20.55M | 12.24M | 9.02M | 8.16M | 7.63M | 6.31M | 282.61K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.15×
EV/EBIT
—
Peer median 11.66×
P/E (TTM)
—
Peer median 10.04×
Peer medians compare against the 298 similar-size Biotechnology companies (of 533 listed).
Key facts
CIK
1477845
CUSIP
03615A108
13F (30d)
58 filings
57 filers
Visit website
Investor relations